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Time from diagnosis to surgery and prostate
cancer survival: a retrospective cohort study
Maria Theresa Redaniel1*, Richard M Martin1, David Gillatt2, Julia Wade1 and Mona Jeffreys1
Abstract
Background: A diagnosis of prostate cancer leads to emotional distress and anxiety, prompting calls for rapid
diagnostic pathways. Nevertheless, it remains unclear what impact time between diagnosis and surgery has upon
prostate cancer survival.
Methods: Using national databases for England (cancer registries, Hospital Episode Statistics and Office of National
Statistics), we identified 17,043 men with prostate cancer, aged 15 years and older, diagnosed in 1996–2009, and
who had surgical resection with curative intent within 6 months of diagnosis. We used relative survival to
investigate associations between waiting times and five- and ten-year survival.
Results: Five- and ten-year relative survival estimates for the total study sample were 1.04 (95% CI: 1.04 to 1.05) and
1.08 (95% CI: 1.06-1.09), respectively. There were no notable differences in survival between patients who had surgery
at 0–3 and 4–6 months after diagnosis. Relative survival was higher among the elderly (>65) and those with well and
moderately differentiated tumours.
Conclusion: The high relative survival in our cohort probably reflects adherence to selection criteria for surgery
among men with localised prostate cancer. Among men treated with surgery within 6 months of diagnosis, we
found little evidence of an association between time from diagnosis to surgery and survival.
Keywords: Time from diagnosis to surgery, Prostate cancer, Cancer survival, Survival inequalities, Surgery
Background
A diagnosis of prostate cancer leads to emotional dis-
tress and anxiety [1-3], a factor which has prompted
calls for rapid cancer patient pathways. However, the ef-
fects of delay between diagnosis and treatment on pros-
tate cancer outcomes have been subject to debate. While
published literature suggest that delay between diagnosis
and radical prostatectomy could cause erectile dysfunc-
tion and urinary incontinence [4], its association with re-
currence and survival remain unclear [5].
In attempts to decrease patient anxiety, expedite diag-
nosis and improve cancer survival, the UK NHS Cancer
Plan (2000) and Cancer Reform Strategy (2007) were
formulated [6,7]. These set maximum targets for waiting
times of 14 days between fast track GP referral and first
hospital appointment, and 31 days between decision to
treat and start of treatment.
However, due to the comparatively lower risk of dying
from prostate cancer, and the complexity of clinical
management options for the disease, the effect of any
waiting time standards to this site have been questioned
[8]. Due to the indolent nature of most localised pros-
tate tumours, watchful waiting and active surveillance
are increasingly being offered as treatment options in
the UK. Nevertheless, prostatectomy remains one of
the main treatment procedures [9], and 19-35% of pa-
tients younger than 70 years of age undergo curative re-
section [10]. Evidence of the association of time from
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(ONS) mortality databases. Prostate cancer was defined
as having a tumour classified in the International Classi-
fication of Diseases (ICD) version 10 as C61.
From all patients who were registered in the population-
based cancer registries, patients diagnosed between January
1, 1996 and December 31, 2009, who were 15 years or
older at the time of diagnosis, and who had surgical resec-
tion with curative intent within 6 months of diagnosis were
included in the study. The age criterion was to allow com-
parability between our results and recent published sur-
vival estimates [11,12]. The 6-month cut-off was based on
clinician perceptions on acceptable time from diagnosis
to surgery not influenced by conditions necessitating
delay (D. Gillatt, personal communications). Patients
diagnosed with secondary cancers, in situ cancers, or diag-
nosed via death certificates only (DCO) or through autopsy
were excluded.
A total of 22,152 men with prostate cancer met these
criteria. From these, we excluded men with time from
diagnosis to surgery of over 6 months (n = 4,171), and a
further 938 patients with negative or zero post-operative
survival times (follow-up). After all exclusions, we were
left with 17,043 patients in the final sample.
Study variables
The time from diagnosis to first curative surgery was de-
fined as the time (in months) between the date of cancer
diagnosis (as recorded in the registry database) and the
date of the first curative resection (as recorded in HES).
The date of diagnosis is defined by the cancer registries
as the date of the first event or event of higher priority
(if recorded within three months of the first event)
among the following: histological or cytological confirm-
ation, admission to the hospital or first consultation at
the outpatient clinic because of the malignancy, or date
of death [13]. In more than 99% of patients, diagnosis
was confirmed through histology of the primary tumour.
Time between diagnosis and surgery were categorized into
0–3 and 4–6 months.
Curative prostate cancer resections were defined as
total / radical prostatectomy (M611), perineal prostatec-
tomy (M614), open excision of prostate (M618), and pros-
tatectomy NEC (M619), based on the Office of Population
Censuses and Surveys (OPCS) Classification of Interven-
tions and Procedures [10].
Post-operative survival was defined as the number of
days between the date of the first curative resection and
the date of outcome (death or censoring). Follow-up was
censored at five- and ten- years, or at the end of the
study period, which was December 31, 2009.
Other covariables in the study were age, region of resi-
dence, ethnicity, tumour differentiation, level of deprivation
and period of cancer plan implementation. Age at cancer
diagnosis was categorized as 15–54, 55–64, 65 years and
above. Geographical region was defined as the patient’s re-
gion of residence at the time of diagnosis. Ethnicity was
self-reported ethnicity, as recorded in the HES database
[14,15]. This was categorized as White and non-White,
and could not be further subdivided due to the small num-
ber of cases in ethnic groups other than White. Only ethni-
city codes in 2005 to 2009 were used as these were deemed
most complete (SWPHO, personal communication) [15],
so ethnicity was coded as “unknown” prior to 2005. Ana-
lyses looking specifically at the effect of ethnicity on the
association of time between diagnosis and surgery with
survival were limited to patients diagnosed between 2005
and 2009.
Tumour differentiation refers to cell differentiation at
the time of tumour biopsy and was classified as well-,
moderately-, poorly- and un-differentiated. The imple-
mentation period of the UK Department of Health
targets was defined as ‘prior to implementation’ (1996–
2000), and ‘after implementation’ (2001–2009). Level of
deprivation was derived from the income component of
the 2007 Index of Multiple Deprivation (IMD) [16], and
was computed for small geographical areas known as
Lower Super Output Areas (LSOAs; mean population =
1500 people) [17]. Quintiles based on English IMD scores
were computed, with the first quintile designated as the
least deprived.
Data analysis
The median time from diagnosis to surgery by each of
the covariables were computed. Using univariable and
multivariable linear regression, coefficients reflecting the
additional days for each category compared to the refer-
ence category were determined for each covariable. All
covariables were controlled for in the multivariable ana-
lysis. For all regression analyses, we used multiple imput-
ation using chained equations (ICE) to account for missing
data on grade and deprivation quintile [18,19]. A total of
20 complete data sets were constructed to reduce sam-
pling variability from the imputation process [20], and the
results were combined using Rubin’s rules [18,19].
Complete estimates of relative survival (where all men
diagnosed between 1996 and 2009 were included, re-
gardless of whether they had full five-year or partial
follow-up) [21], were computed using the STRS com-
mand in STATA, version 12 [22]. Relative survival is a
measure of survival, having accounted for underlying
mortality rates. It is the ratio of the observed survival of
cancer patients to the probability of survival that would
have been expected if patients had experienced the same
survival probability as the general population [23]. Sur-
vival probabilities were estimated at intervals of 6 months
in the first year, then yearly up to 10 years. We used
age-, region- and calendar year-specific UK life tables for
males [24] to account for the differences in the underlying
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mortality and used the Ederer II method [23] to determine
expected survival.
To investigate the effect of time between diagnosis
and surgery on survival, the data were stratified ac-
cording to categories of time to surgery (0–3 and 4–
6 months) and relative survival estimates were visu-
ally inspected. To account for waiting time paradox
(wherein patients offered surgery within few weeks of
diagnosis could be presenting more severe manifestations
of the disease), a sensitivity analyses was done using more
refined time intervals (1, 2, 3–4 and 5–6 months). We
limited the analysis to computing relative survival esti-
mates because the excess mortality in the study population
is negative (i.e. the mortality in our study population is
lower than that of the general population) which causes
model convergence problems (P. Dickman and P. Lambert,
personal communication).
Ethics/regulatory approvals
This project was approved by the Faculty of Medicine
and Dentistry Committee for Ethics, University of Bristol
(101153), the NHS South Central – Berkshire B Research
Ethics Board (11/SC/0387) and the National Information
Governance Board (NIGB, ECC 7-02(d)/2011).
Consent
We made use of cancer registry data that were provided
to us in anonymised form. The use of this data is regu-
lated by the Confidentiality Advisory Group (CAG,
formerly NIGB) of the Health Research Authority and
does not require individual patient consent.
Results
Overall, the men had a median time from diagnosis to
curative surgery of 95 days (interquartile range, IQR: 70 to
125). Longer time from diagnosis to surgery were associ-
ated with increasing age, residence in the North East,
Yorkshire and the Humber and the West Midlands and
having well differentiated tumours (Table 1). There were
no differences in time between diagnosis and surgery by
ethnicity, deprivation and between the Cancer Plan imple-
mentation periods.
Five- and ten-year relative survival ratio for the total
study sample were 1.04 (95% CI: 1.04 to 1.05) and 1.08
(95% CI: 1.06-1.09), respectively. There were no notable
differences in five- and ten-year survival between men
who had surgery at 0–3 and 4–6 months (Table 2).
Survival was higher with increasing age, with men
65 years and older having 8–19 percentage points in-
creased survival compared to men aged 15–54 years.
Men with well and moderately differentiated tumours
had 5–15 percentage points higher survival than those
with poor- and undifferentiated tumours. There was no
change in five-year relative survival after the cancer plan
was implemented, but a 3–9 percentage point increase
in survival was observed after nine-years.
Relative survival estimates were similar even if finer
time categories were used (data not shown), with the
exception of patients with poor- and undifferentiated tu-
mours. Patients with poor- and undifferentiated tumours
who had surgery within one month of diagnosis had a five-
year relative survival of 0.81 (95% CI: 0.56 to 0.96), indicat-
ing that the waiting time paradox applies to this group.
Discussion
This study provides evidence that within 6 months of
diagnosis, time between diagnosis and surgery does not
impact on survival of men with prostate cancer. Relative
survival was above 100%, indicating that these men were
healthier than the general population, irrespective of age,
region of residence, tumour differentiation, ethnicity,
level of deprivation and whether they were diagnosed
before or after the Cancer Plan implementation.
Our findings are in agreement with current literature.
A recent review found no association between delay in time
from diagnosis to radical prostatectomy and observed and
cancer-specific survival [5]. Nevertheless, a delay of more
than 9 months was reported to increase biochemical recur-
rence rates among men with intermediate risk disease [25],
and a delay of more than 6 months was associated with dis-
ease upgrading among low-risk patients [26]. These results
suggest that while delayed treatment affects cancer progres-
sion, it does not have a significant impact on survival.
Whilst most men in our study would not have re-
ceived watchful waiting/active surveillance (as they all
had surgery within 6 months), our data, nevertheless,
reflect the findings of recent clinical trials which found
little benefit of radical prostatectomy compared to watch-
ful waiting among prostate cancer patients, at least in the
medium term [27,28].
The high relative survival ratios (above 1.00) reflect the
fact that men who are offered surgery are relatively fit with-
out co-morbidities, with a realistic prospect of disease con-
trol and long life expectancy, relative to the patient’s age
[9]. These criteria for surgery could likewise be the reason
for better survival among elderly patients in this cohort.
In our cohort, older men (65 years and above) have
higher relative survival compared to younger men (15–
54 years old). This implies that older men with prostate
cancer who are offered surgery are healthier and have better
survival than their contemporaries in the same age group in
the general population. Elderly men who are offered surgery
might have less severe comorbidities, if any, and have
higher life expectancy. In contrast, younger men with pros-
tate cancer have the same level of survival compared to
men of the same age group in the general population.
Our results show that factors other than waiting times
may be stronger predictors of prostate cancer survival,
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particularly tumour differentiation. It is widely accepted
that a high Gleason score (low tumour differentiation) is
indicative of poorer prognosis [29]. Other factors such
as stage and the presence of co-morbidities could like-
wise affect survival and require further research.
Our study is one of the few that have looked at the ef-
fect of time between diagnosis and surgery on prostate
cancer survival, but it is not without limitations. We used
routinely collected data from cancer registries and HES in
England, which is known to be of high completeness and
Table 1 The distribution and association of selected risk factors with diagnostic to curative surgery waiting times,
prostate cancer, 1996-2009








15 - 54 1990 11.68 89 (65–119) 0.00 0.00
55 - 64 8839 51.86 94 (70–125) 4.60 2.90 to 6.30 4.94 3.21 to 6.68
65 and above 6214 36.46 97 (70–126) 5.67 4.14 to 7.21 6.24 4.69 to 7.78
Region of residence
London 1971 11.56 93 (66–124) 0.00 0.00
North East 940 5.52 104 (80–133) 10.73 3.30 to 18.16 11.43 4.61 to 18.25
North West 1245 7.31 85 (62–114) −6.63 −10.29 to −2.97 −6.08 −9.23 to −2.93
Yorkshire and the Humber 1914 11.23 102 (77–131) 9.07 5.38 to 12.76 9.44 6.24 to 12.63
East Midlands 1200 7.04 88 (67–115.5) −2.79 −6.49 to 0.90 −2.78 −6.20 to 0.64
West Midlands 2012 11.81 104 (74–132) 8.88 5.17 to 12.60 9.22 6.06 to 12.38
East of England 2002 11.75 96 (73–126) 4.35 −0.75 to 9.45 6.21 2.97 to 9.45
South East 3413 20.03 91 (68–124) 0.65 −3.18 to 4.48 0.80 −2.62 to 4.23
South West 2346 13.77 91 (68–119) −2.49 −6.19 to 1.21 −2.86 −6.19 to 0.47
Ethnicity, major groups3
White 6671 68.50 90 (67–118) 0.00 0.00
Non-White 446 4.58 94 (69–125) 3.73 −1.62 to 9.08 3.45 −1.61 to 8.51
Unknown 2621 26.92 89 (66–117) −0.89 −3.07 to 1.30 −0.11 −2.17 to 1.94
Tumour differentiation
Well differentiated 837 4.91 98 (73–130) 0.00 0.00
Moderately differentiated 4857 28.50 98 (74–128) −2.95 −7.02 to 1.12 −4.98 −8.53 to −1.43
Poor- & undifferentiated 1397 8.20 91 (69–117) −7.81 −12.28 to −3.35 −9.71 −14.25 to −5.17
Unknown 9952 58.39 92 (68–124)
Deprivation quintile
1 - least deprived 4499 26.40 93 (69–125) 0.00 0.00
2 4235 24.85 94 (69–124) −0.37 −1.54 to 0.79 −0.26 −1.52 to 1.00
3 3477 20.40 95 (70–125) 0.33 −1.68 to 2.35 0.54 −1.34 to 2.42
4 2581 15.14 95 (70–125) 1.15 −0.83 to 3.13 1.09 −0.52 to 2.70
5 - most deprived 1737 10.19 98 (72–130) 3.67 1.63 to 5.72 2.49 0.26 to 4.72
Unknown 514 3.02 95 (65–132)
Cancer plan implementation period
Prior to implementation
(1996–2000)
1701 9.98 98 (69–131) 0.00 0.00
After implementation
(2001–2009)
15342 90.02 94 (70–124) −1.86 −5.14 to 1.42 2.91 −0.36 to 6.18
1adjusted for all the other variables in the table.
2represents the additional days waiting for each category compared to the reference category.
3all codes prior to 2005 were recoded as unknown; represents only data from 2005–2009.
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have low percentage of death certificate only cases [30].
However, it does not contain all information pertinent to
patient care (PSA testing, Gleason score, stage, comorbidi-
ties and functional state), which could have explained the
timeliness of treatment. We also do not have information
on other forms of treatment as only Cancer registry-HES
inpatient data could be provided. All our results relate
to time between diagnosis and surgery not exceeding
Table 2 Five- and ten-year relative survival ratio by selected risk factors and waiting time cut-offs, prostate cancer with
curative surgery, 1996-2009
Variable Five-year survival Ten-year survival

















Overall 1.04 1.03 to 1.04 1.05 1.04 to 1.05 1.07 1.05 to 1.09 1.08 1.06 to 1.10
Age group
15-54 0.99 0.98 to 1.01 1.01 0.99 to 1.01 0.99 0.95 to 1.02 1.00 0.93 to 1.03
55-64 1.02 1.02 to 1.03 1.03 1.02 to 1.04 1.03 1.00 to 1.06 1.06 1.03 to 1.08
65 and above 1.07 1.06 to 1.08 1.09 1.08 to 1.10 1.18 1.13 to 1.22 1.15 1.10 to 1.19
Region of Residence
London 1.04 1.02 to 1.06 1.06 1.04 to 1.07 1.10 1.04 to 1.14 1.03 0.95 to 1.10
North East 1.03 0.99 to 1.06 1.06 1.04 to 1.07 1.13 0.99 to 1.19 1.12 1.01 to 1.17
North West 1.04 1.00 to 1.06 1.05 1.02 to 1.08 1.13 1.01 to 1.20 1.10 0.87 to 1.21
Yorkshire and the Humber 1.05 1.02 to 1.06 1.06 1.04 to 1.07 1.02 0.89 to 1.10 1.05 0.98 to 1.11
East Midlands 1.05 1.02 to 1.06 1.04 1.00 to 1.06 1.10 0.99 to 1.15 1.13 1.07 to 1.17
West Midlands 1.04 1.01 to 1.06 1.06 1.04 to 1.07 1.13 1.05 to 1.18 1.10 1.02 to 1.15
East of England 1.03 1.00 to 1.04 1.02 1.00 to 1.04 1.01 0.94 to 1.07 1.06 1.00 to 1.11
South East 1.03 1.02 to 1.04 1.05 1.03 to 1.06 1.04 0.97 to 1.09 1.10 1.06 to 1.14
South West 1.03 1.01 to 1.04 1.05 1.03 to 1.06 1.10 1.05 to 1.14 1.10 1.04 to 1.14
Ethnicity1
White 1.04 1.02 to 1.05 1.06 1.04 to 1.07
Non-White 1.08 1.04 to 1.09 1.07 1.02 to 1.08
Unknown 1.06 1.05 to 1.07 1.07 1.05 to 1.07
Tumour differentiation
Well differentiated 1.04 1.01 to 1.06 1.05 1.03 to 1.07 1.12 1.06 to 1.16 1.12 1.07 to 1.16
Moderately differentiated 1.04 1.02 to 1.05 1.05 1.04 to 1.06 1.10 1.06 to 1.13 1.09 1.05 to 1.12
Poor- & undifferentiated 0.98 0.94 to 1.01 1.00 0.96 to 1.03 0.95 0.83 to 1.04 0.95 0.82 to 1.04
Unknown 1.04 1.03 to 1.05 1.05 1.05 to 1.06 1.06 1.02 to 1.09 1.09 1.05 to 1.12
Deprivation quintile
1 – least deprived 1.04 1.03 to 1.05 1.05 1.04 to 1.06 1.07 1.00 to 1.12 1.10 1.04 to 1.14
2 1.04 1.03 to 1.05 1.05 1.04 to 1.06 1.10 1.04 to 1.14 1.12 1.07 to 1.15
3 1.03 1.01 to 1.04 1.04 1.03 to 1.05 1.05 0.97 to 1.11 1.04 0.97 to 1.09
4 1.04 1.02 to 1.05 1.05 1.04 to 1.06 1.10 1.04 to 1.15 1.09 1.02 to 1.13
5 – most deprived 1.03 1.00 to 1.05 1.06 1.04 to 1.07 1.02 0.88 to 1.10 1.12 1.06 to 1.16
Unknown 1.01 0.97 to 1.04 1.04 1.00 to 1.07 1.04 0.97 to 1.09 1.06 0.99 to 1.11
Cancer plan implementation period
Prior to implementation
(1996–2000)
1.03 1.00 to 1.04 1.04 1.02 to 1.05 1.05 1.02 to 1.08 1.06 1.03 to 1.09
After implementation
(2001–2009)
1.04 1.03 to 1.04 1.05 1.05 to 1.06 1.08* 1.05 to 1.11 1.11* 1.09 to 1.12
*represents 9-year survival.
1all codes prior to 2005 were recoded as unknown; represents only data from 2005–2009.
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6 months, and time interval beyond 6 months could be
hazardous to the patient.
Conclusions
Our study shows that within a period of 6 months after
diagnosis, there is little evidence of an association between
time from diagnosis to surgery and survival. More research
is needed to fully understand the role of clinical and health
care related factors in prostate cancer survival.
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